Novo Nordisk’s CagriSema led to 23% weight loss but missed industry expectations, sending its stock tumbling. The Danish drugmaker released the highly anticipated results of its Phase 3 trial of the ...

Novo Nordisk links next-gen obesity drug to 22% weight loss at Week 36, sending stock up 11% Since Zepbound beat Wegovy in a head-to-head weight loss trial in December 2024, Novo has been ...

Eli Lilly (LLY 0.40%) and Novo Nordisk (NVO 1.97%) are two phenomenal growth stocks that investors probably can't go wrong ...

In Q1 2024, sales of Novo's Wegovy and Ozempic totaled around $5.6 billion. This compares to $2.3 billion in sales for Lilly's Zepbound and Mounjaro.

ROME (Reuters) -Italian authorities on Monday appointed a special commissioner to help Danish drugmaker Novo Nordisk speedily deliver its promised 2 billion-euro ($2.34 billion) investment in a ...

Novo Nordisk to present phase 3 trials across hemophilia portfolio, reinforcing commitment to research in rare blood disorders, at ISTH 2025. PR Newswire. PLAINSBORO, N.J., June 6, 2025.

Novo Nordisk currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here . 7 Best Stocks for the Next 30 Days ...

Novo’s phase 3 failure will spur an impairment loss of 5.7 billion Danish kroner ($816.5 million) for the second quarter of this year, according to a June 26 company release.

According to terms announced Thursday, Novo Nordisk will pay $38.25 cash for each share of Lexington, Massachusetts-based Dicerna. That price is an 80% premium to Dicerna’s closing stock price ...

Novo Nordisk A/S agreed to buy an experimental blood-pressure medicine from KBP Biosciences for as much as $1.3 billion, extending a string of recent deals to bolster its drug pipeline.